🟢 Novo Nordisk is trading 4.05% up today after CHMP recommended Frehemgo EU authorisation

Novo Nordisk is trading 4.05% up now at $43.40 after the EMA’s CHMP recommended EU marketing authorisation for Frehemgo, its haemophilia A treatment.

• The recommendation covers adults and children, including patients with or without inhibitors, and follows positive FRONTIER trial results.
• The S&P 500, Nasdaq Composite, and Dow Jones are all up more than 0.5%, supporting the broader rally.
• Trading-volume data was unavailable; confidence is medium.